Compounded Semaglutide (What It Is and Its Current Status)

By DoseGauge Editorial · Updated 2026-06-12 · 5 min read

Compounded semaglutide is semaglutide prepared by a compounding pharmacy or outsourcing facility rather than supplied as the brand manufacturer's finished product. It is often distributed as a vial of solution or powder that the user draws into a syringe, sometimes reconstituting it first. Its availability and legal footing changed after the FDA declared the semaglutide injection shortage resolved in early 2025. The status described below is as of June 2026 and is actively changing. This page explains what compounded semaglutide is and where the regulatory situation stands. It does not tell you where to obtain it, whether to use it, or that any particular source is legal.

What compounded semaglutide is

Compounding is the practice of a licensed pharmacy or outsourcing facility preparing a medication to meet a need that the approved product does not. United States law describes two categories. Section 503A covers traditional compounding by a state-licensed pharmacy or physician, generally for an individual patient. Section 503B covers registered outsourcing facilities that can compound in larger batches under tighter manufacturing standards.

Compounded semaglutide is semaglutide produced under one of those frameworks rather than as Ozempic or Wegovy. In practice it has been supplied as a vial, sometimes as a solution and sometimes as a powder that the user reconstitutes with bacteriostatic water before drawing a dose. Compounded products are not FDA-approved: the agency does not review individual compounded preparations for safety, effectiveness, or quality before they are dispensed.

Why it became common

Injectable semaglutide was on the FDA drug shortage list during the surge in demand across roughly 2022 to 2024. While an approved drug is officially in shortage, federal law gives compounders limited room to prepare a version of it, which would otherwise be restricted because compounders generally may not make a product that is "essentially a copy" of a commercially available approved drug. The shortage created that room, and a large market for compounded semaglutide developed alongside telehealth prescribing.

That permission was always tied to the shortage. Once the shortage ended, the legal basis that had allowed broad compounding of semaglutide narrowed sharply.

The current status

The FDA declared the semaglutide injection product shortage resolved on February 21, 2025, removing it from the drug shortage list. The agency then set end dates for the enforcement discretion it had extended during the shortage: for state-licensed pharmacies and physicians compounding under section 503A, that period ended on April 22, 2025; for outsourcing facilities compounding under section 503B, it ended on May 22, 2025.

Industry groups challenged the resolution in court. In Outsourcing Facilities Association v. FDA, a federal court declined to block the FDA's timeline in 2025, leaving the agency's restrictions in place. Through 2025 and into 2026 the FDA continued enforcement, including warning letters to compounders and telehealth sellers, and the agency moved to formally exclude semaglutide from the list of bulk substances that 503B outsourcing facilities may use, citing no clinical need to compound it from bulk. Separately, the brand manufacturer has pursued civil litigation against sellers of compounded versions.

The practical effect as of June 2026: the shortage-based pathway that made broad compounding of semaglutide possible has closed, and compounding of products that are essentially copies of the approved drug is restricted and subject to enforcement. Narrow exceptions can still exist (for example, a documented patient-specific clinical need for a change the approved product cannot meet), but those are situation-specific. This area is changing, and the status of any specific product or seller depends on current FDA action and the facts of that case. Nothing here establishes that a given compounded product is legal.

Why reconstitution math matters for vial users

If you hold a compounded vial that is supplied as a powder, you have to add the diluent yourself, and the volume you add sets the concentration. That concentration is what converts a milligram dose into a number of syringe units. Get the concentration wrong and every unit count is wrong. The calculator converts your vial strength and water volume into the draw volume and units, so the arithmetic is explicit rather than guessed. It computes from your inputs and does not recommend a dose or a source.

Frequently asked questions

Is compounded semaglutide legal?

It depends on the source and current FDA enforcement, and it is changing. The shortage that allowed broad compounding of semaglutide was declared resolved on February 21, 2025, and the enforcement discretion that went with it ended in spring 2025. Compounding a product that is essentially a copy of the approved drug is generally restricted outside of narrow, situation-specific exceptions. This page cannot tell you that any particular product is legal.

What is the difference between 503A and 503B compounding?

Section 503A covers traditional compounding by a state-licensed pharmacy or physician, typically for an individual patient. Section 503B covers registered outsourcing facilities that compound in larger batches under stricter manufacturing requirements. Both faced enforcement deadlines after the semaglutide shortage was declared resolved in 2025.

Is compounded semaglutide FDA-approved?

No. Compounded preparations are not FDA-approved. The FDA does not review individual compounded products for safety, effectiveness, or quality before they are dispensed. That is true regardless of the shortage status.

Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.